hrp0082p1-d3-230 | Reproduction (2) | ESPE2014

Increasing Incidence of Premature Thelarche in the Central Denmark Region? Who Evolve into Precocious Puberty?

Somod Mia Elbek , Vestergaard Esben Thyssen , Kristensen Kurt , Birkebaek Niels Holtum

Background: Premature thelarche (PT) may evolve into precocious puberty (PP). The incidence of PP in girls has increased during the last two decades. The epidemiology of PT in the first years of life is less well described.Objective and hypotheses: We aimed to identify 0–6 year old girls referred to paediatric evaluation for PT in order to examine if the number of girls with PT is increasing, and to describe clinical characteristics of the girls wit...

hrp0084p2-543 | Puberty | ESPE2015

The Endocrine Response to a Gonadotropin Releasing Hormone (GnRH) Test: Establishing a Reference Interval in Healthy Girls below 6 Years of Age

Vestergaard Esben , Somod Mia , Kamperis Kostas , Kastberg Karin , Rittig Soren , Kristensen Kurt , Birkebaek Niels

Background: Premature thelarche and precocious puberty are frequently diagnosed even in girls below 6 years of age. A GnRH test is often included in the diagnostic work up. Interpretation of the GnRH test in girls below 6 years of age is, however, difficult, because the reference interval has not been established in this age group.Objective and hypotheses: To establish the normal endocrine response to a GnRH test in healthy girls below 6 years of age.</p...

hrp0092p1-136 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

Serum Estradiol is Associated with Inhibin B in Healthy 1-6 Years Old Girls

Birkebaek Niels H. , Schørring Mia E. , Frederiksen Hanne , Kamperis Konstantinos , Kristensen Kurt , Rittig Søren , Juul Anders , Vestergaard Esben T

Background: The female gonadal axis is activated in mini-puberty and thereafter it is quiescent until puberty. We have shown that many girls with no clinical sign of puberty in the age group 1-6 yr. have a rather strong luteinizing hormone (LH) and follicle stimulating hormone (FSH) response to a gonadotropin releasing hormone (GnRH) test. However, stimulated LH and FSH values decreased in the age interval 1-6 yr and no LH/FSH values rose above 0.43. Serum est...

hrp0092fc14.5 | GH and IGF5 | ESPE2019

OOnce-weekly Somapacitan vs Daily Growth Hormone (Norditropin®) in Childhood Growth Hormone Deficiency: One-year Results from a Randomised Phase 2 Trial

Sävendahl Lars , Battelino Tadej , Horikawa Reiko , Juul Rasmus Vestergaard , Rasmussen Michael Højby , Saenger Paul

Daily injections are required for human growth hormone (GH) replacement therapy. Somapacitan is a long-acting GH derivative being developed for once-weekly dosing in adults and children using a proven protraction method, currently successfully in use to extend the half-life of insulin and glucagon-like peptide 1.To evaluate the efficacy and safety of three different once-weekly somapacitan doses compared with Norditropin®, a daily GH, ove...

hrp0089fc4.6 | GH &amp; IGFs | ESPE2018

Absorption and Excretion of Somapacitan, a Long-Acting Growth Hormone (GH) Derivative

Rasmussen Michael Hojby , Damholt Birgitte Bentz , Helleberg Hans , Bjelke Mads , Suresh Swapna , Juul Rasmus Vestergaard , Hollensen Christian

Background: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative in clinical development for once-weekly administration in patients with GH deficiency (GHD). Clinical data in healthy subjects, and adults and children with GHD showed that once-weekly somapacitan injections were well tolerated with no clinically significant safety or local tolerability issues. A sustained dose-dependent IGF-I response supports a once-weekly treatment regimen.<p class="a...

hrp0084p1-131 | Thyroid | ESPE2015

Increased Detection Rate of Paired Box Domain Gene Mutations by Application of Multiplex Ligation-Dependent Probe Amplification Analysis in Patients with Primary Congenital Hypothyroidism and Thyroid Dysgenesis

Kumorowicz-Czoch Malgorzata , Hermanns Pia , Madetko-Talowska Anna , Pohlenz Joahim

Background: The contribution of mutations in paired box domain (PAX8) gene in children with congenital hypothyroidism (CH) and thyroid dysgenesis (TD) still remains a subject of interest of researchers. While quantitative PCR and direct sequencing concentrate on single gene fragment analysis and identification of point mutations, multiplex ligation-dependent probe amplification (MLPA) analysis might improve the detection rate of PAX8 mutations in patients wit...

hrp0084p2-532 | Puberty | ESPE2015

Determination of Final Height in Girls with Precocious Puberty. Which is the Most Accurate Method?

Quiroga Daniela , Pinochet Constanza , Cerda Jaime , Cattani Andreina , Garcia Hernan

Background: Central precocious puberty (CPP) is a common condition in girls and has been associated with deterioration of final height (FH). Height prognosis (HP) is critical for the decision of treatment in CPP. There are several methods for predicting FH in CPP but none is completely reliable. Most methods consider bone age (BA), which is very imprecise, but there is no consensus on which method is the best to estimate FH.Objective: To compare the accu...

hrp0097p1-315 | Growth and Syndromes | ESPE2023

Which Method is More Effective in Predicting Adult Height in Pubertal Girls Treated with Gonadotropin-Releasing Hormone Agonist?

Akın Kağızmanlı Gözde , Deveci Sevim Reyhan , Besci Özge , Yüksek Acinikli Kübra , Hazal Buran Ayşen , Mert Erbaş İbrahim , Böber Ece , Demir Korcan , Anık Ahmet , Abacı Ayhan

Purpose: The aim of the present study was to determine the efficiency of three different predictive models [Bayley-Pinneau (BP), Roche-Wainer-Thissen (RWT), and Tanner-Whitehouse 2 (TW2)] by comparing their predictions with near-adult height (NAH) data of girls who received gonadotropin-releasing hormone agonist (GnRHa) therapy.Methods: Clinical findings were retrospectively analyzed. Bone age (BA) was determined by thre...

hrp0092p2-240 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Bone Age Determination in Girls with Early Puberty and Limitations of Adult Height Prediction: Can Automated Evaluation (BoneXpert™)be a Solution?

Yesiltepe-Mutlu Gul , Capaci Merve , Uzunkopru Gizem , Hatun Sükrü

Introduction: One of the factors affecting the treatment decision in early puberty is bone age (BA) evaluation and adult height prediction (AHP), accordingly. These calculations have certain limitations. In this study, we aimed to compare the AHP results calculated by Bayley-Pinneau (BP) and Roche-Wainer-Thissen(RWT) methods based on BA evaluation by using Greulich-Pyle(GP) atlas and BoneXpert™ software.Methods: A t...

hrp0097p1-541 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Prediction of Adult Height Based on Automated Bone Age Estimation in Early Puberty: A Single-Center Prospective Study

Huseyin Yigit Murat , Yesiltepe Mutlu Gul , Eviz Elif , Hatun Sukru

Introduction: In cases of precocious puberty, an important factor in making treatment decisions is when adult height estimates based on bone age (BA) determination are behind midparental height. In Turkey, clinicians often use the Greulich Pyle (GP) atlas to determine BA, which can lead to significant differences between assessors. The aim of this study was to compare estimated adult height (EAH) calculations based on BA determined by the automated BoneXpert m...